Anthony Aiudi
Investment Professional @ Morningside
Anthony Aiudi is a Series A investor at Morningside focused on Biotechnology and Medical. Anthony Aiudi - Investment Professional @ Morningside
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Anthony Aiudi invests in
Stages Anthony Aiudi invests in
Countries Anthony Aiudi invests in
Investment Focus
Industry
- Biotechnology 3 (50%)
- Medical 2 (33%)
- Therapeutics 2 (33%)
- Pharmaceutical 2 (33%)
- Beauty 1 (17%)
Stage
- Series A 2 (33%)
- Series B 2 (33%)
- Series C 1 (17%)
- Series D 1 (17%)
Country
- United States 3 (50%)
- Australia 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $315M / Series D / Jul 15, 2026 | |
|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $112M / Series C / Feb 03, 2025 | |
Valitor
|
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currentlyhave three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products. | $28M / Series B / Oct 05, 2022 | |
Otolith Labs
|
Otolith Labs has developed a novel wearable medical device that is on track to be the first FDA approved device for the treatment of vertigo through the De Novo process in 2023. The technology provides immediate relief of symptoms in approximately 80% of vertigo cases based on pilot clinical data. Otolith Labs has received $1.8 million in contractsfrom the US Department of Defense to further develop the technology for their personnel needs. | $20M / Series A / Sep 07, 2022 | |
|
AdvanCell
|
AdvanCell is an Australian radiopharmaceutical firm in the clinical stages that has developed the Targeted Alpha Therapy platform technology, a cutting-edge cancer treatment. | $12.5M / Series B / Aug 23, 2022 | |
Fount Bio
|
Fount Bio is a life science company that applies proprietary advances in glycopolymer research for skin health. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts, United States. | $8.2M / Series A / Jul 01, 2021 |
Co-Investors
About Morningside
Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically.Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology.Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
Morningside Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Anthony Aiudi
Investment Professional
|
|||
Mick Sawka
Investment Manager
|
|||
Gerald Chan
Co-Founder, Investment Director & Board Member
|
|||
Justin Burns
Investment Professional
|
|||
|
Michael Xue
Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Anthony Aiudi invest in?
Anthony Aiudi invests primarily in Biotechnology, Medical and Therapeutics startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Anthony Aiudi last invest?
The most recent investment recorded for Anthony Aiudi closed in Jul 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
